Startseite › Nichtkleinzelliges Lungenkarzinom › Texas › Dallas
Klinische Studien zu Nichtkleinzelliges Lungenkarzinom in Dallas, TX
52 Studien zu Nichtkleinzelliges Lungenkarzinom suchen Teilnehmer an Standorten in und um Dallas (im Umkreis von ca. 30 Meilen). Öffnen Sie eine Studie, um Teilnahmevoraussetzungen und Kontaktdaten des Studienteams zu sehen.
Offizieller Studientext (Englisch)
A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 2
- Texas Oncology - Dallas - Worth Street /ID# 278947, Dallas
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
Teilnehmer gesuchtPhase 3
- Parkland Memorial Hospital, Dallas
- UT Southwestern Simmons Cancer Center - RedBird, Dallas
- UT Southwestern/Simmons Cancer Center-Dallas, Dallas
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Teilnehmer gesuchtPhase 1/2
- UT Southwest Simmons Cancer Center, Dallas
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
Teilnehmer gesuchtPhase 3
- Texas Oncology - DFW ( Site 8103), Dallas
- UT Southwestern Medical Center ( Site 0190), Dallas
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Teilnehmer gesuchtPhase 1
- Exelixis Clinical Site #89, Dallas
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- SCRI at Mary Crowley, Dallas
- University of Texas Southwestern Medical Center, Dallas
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
Teilnehmer gesuchtPhase 3
- Texas Oncology Dallas, Dallas
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 3
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- und 2 weitere
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- Texas Oncology - DFW, Dallas
- und 2 weitere
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 2
- Parkland Health and Hospital System, Dallas
- Texas Oncology DFW, Dallas
- UT Southwestern Medical Center, Dallas
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1
- Research Site, Dallas
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Teilnehmer gesuchtPhase 1/2
- Baylor, Scott and White Research Institute, Dallas
A Study of Gilteritinib in Adults With Advanced ALK-positive Non-small Cell Lung Cancer (NSCLC)
Teilnehmer gesuchtPhase 1
- UT Southwestern Medical Center at Dallas, Dallas
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
Teilnehmer gesuchtPhase 3
- Texas Oncology Sammons Cancer Center, Dallas
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Teilnehmer gesuchtPhase 3
- Clinical Study Site, Dallas
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
Teilnehmer gesuchtPhase 1
- NEXT - Dallas, Dallas
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Teilnehmer gesuchtPhase 2/3
- Texas Oncology - Dallas Fort Worth (DFW) - Baylor Charles A. Sammons Cancer Center, Dallas
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Teilnehmer gesuchtBeobachtungsstudie
- UT Southwestern Medical Center, Dallas
A Study of KK2269 in Adult Participants With Solid Tumors
Teilnehmer gesuchtPhase 1
- The University of Texas Southwestern Medical Center, Dallas
Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Mary Crowley Cancer Research, Dallas
A Phase 1/1b Study of IAM1363 in HER2 Cancers
Teilnehmer gesuchtPhase 1
- Mary Crowley Cancer Research, Dallas
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Teilnehmer gesuchtPhase 3
- The University of Texas Southwestern Medical Center at Dallas, Dallas
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Teilnehmer gesuchtPhase 1
- Ut Southwestern, Dallas
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Teilnehmer gesuchtPhase 3
- Texas Oncology, Dallas
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
Teilnehmer gesuchtPhase 2
- Baylor Charles A. Sammons Cancer Center, Dallas
A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer
Teilnehmer gesuchtPhase 1/2
- Texas Oncology - DFW, Dallas
A Study of DM005 in Patients With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Sarah Cannon Research Institute at Mary Crowley, Dallas
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Teilnehmer gesuchtPhase 1/2
- Mary Crowley Cancer Research, Dallas
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas
- UT Southwestern Medical Center - Redbird, Dallas
- Univ. of TX Southwestern Medical Center - Zale Lipshy University Hospital, Dallas
- und 2 weitere
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Teilnehmer gesuchtPhase 2
- Texas Oncology - DFW, Dallas
Feasibility Study of Personalized Ultra-fractionated Stereotactic Ablative Radiotherapy (PULSAR) for Cancers of the Central Lung
Teilnehmer gesuchtFrühe Phase 1
- University of Texas Southwestern Medical Center, Dallas
LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC
Teilnehmer gesuchtPhase 3
- Old Parkland Hospital Hematology Oncology Clinic, Dallas
- UT Southwestern Medical Center, Dallas
Study of XB010 in Subjects With Solid Tumors
Teilnehmer gesuchtPhase 1
- Baylor University Medical Center, Dallas
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- NEXT Texas LLC - Dallas, Dallas
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
Teilnehmer gesuchtPhase 1
- UT Southwestern Simmons Cancer Center, Dallas
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Teilnehmer gesuchtPhase 1
- University of Texas Southwestern Medical Center /ID# 251974, Dallas
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Teilnehmer gesuchtPhase 1
- Sarah Cannon Research Institute at Mary Crowley, Dallas
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Teilnehmer gesuchtPhase 1
- Sarah Cannon Research Institute at Mary Crowley, Dallas
A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements
Teilnehmer gesuchtPhase 1/2
- UT Southwestern Medical Center, Dallas
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Teilnehmer gesuchtPhase 1/2
- Mary Crowley Cancer Research, Dallas
A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma
Teilnehmer gesuchtPhase 2
- UT Southwestern Medical Center, Dallas
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Teilnehmer gesuchtPhase 2
- University of Texas Southwestern Medical Center, Dallas
JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer
Teilnehmer gesuchtPhase 3
- University of Texas Southwestern Medical Center, Dallas
A Study of VET3-TGI in Patients With Solid Tumors
Teilnehmer gesuchtPhase 1
- Mary Crowley Cancer Research, Dallas
A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1
- NEXT Dallas, Dallas
A Phase 1/2 Clinical Trial to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMBD-501 in Patients With HER3-Expressing Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Research Site, Dallas
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1/2
- NEXT Oncology - Dallas, Dallas
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
Teilnehmer gesuchtPhase 1/2
- NEXT Oncology Dallas, Dallas
A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Teilnehmer gesuchtPhase 1
- Dren Investigational Site, Dallas
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Teilnehmer gesuchtPhase 1/2
- Research Site 120, Dallas
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Teilnehmer gesuchtBeobachtungsstudie
- Massive Bio SYNERGY-AI site, Dallas
Predicting Responsiveness in Oncology Patients Based on Host Response Evaluation During Anti Cancer Treatments, Using Multiomics
Teilnehmer gesuchtBeobachtungsstudieGesunde Freiwillige willkommen
- Baylor Scott and White Research Institute, Dallas
Nichtkleinzelliges Lungenkarzinom-Studien in anderen Städten
- Houston, TX145 Studien
- New York City, NY121 Studien
- Arlington, VA104 Studien
- Nashville, TN97 Studien
- Boston, MA90 Studien
- Los Angeles, CA87 Studien
- St. Louis, MO73 Studien
- Chicago, IL61 Studien
- Baltimore, MD60 Studien
- San Antonio, TX59 Studien
- Columbus, OH57 Studien
- Washington, DC55 Studien
Weitere Studien in Dallas
- Brustkrebs55 Studien
- Metastasierender Krebs42 Studien
- Herzinsuffizienz42 Studien
- Krebs (alle Arten)37 Studien
- Prostatakrebs36 Studien
- Kolorektales Karzinom33 Studien
- Adipositas30 Studien
- Eierstockkrebs28 Studien
- Lungenkrebs27 Studien
- Blasenkrebs27 Studien
- Endometriumkarzinom24 Studien
- Nierenkrebs (Nierenzellkarzinom)23 Studien
Quelle: ClinicalTrials.gov, Daten abgerufen am 06.10.2026. Jede Studie legt ihre eigenen Teilnahmevoraussetzungen fest; das Studienteam entscheidet über die Zulassung.